Sequoia Financial Advisors LLC Cuts Stock Position in Privia Health Group, Inc. (NASDAQ:PRVA)

Sequoia Financial Advisors LLC trimmed its holdings in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 8.8% in the fourth quarter, Holdings Channel reports. The firm owned 27,892 shares of the company’s stock after selling 2,675 shares during the period. Sequoia Financial Advisors LLC’s holdings in Privia Health Group were worth $642,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in PRVA. Tower Research Capital LLC TRC boosted its position in shares of Privia Health Group by 171.1% in the first quarter. Tower Research Capital LLC TRC now owns 1,578 shares of the company’s stock worth $44,000 after buying an additional 996 shares during the period. Point72 Hong Kong Ltd acquired a new position in Privia Health Group during the 1st quarter worth approximately $47,000. Neo Ivy Capital Management purchased a new position in Privia Health Group in the 2nd quarter worth approximately $53,000. Benjamin Edwards Inc. acquired a new stake in Privia Health Group in the second quarter valued at approximately $58,000. Finally, Jefferies Financial Group Inc. purchased a new stake in shares of Privia Health Group during the fourth quarter valued at approximately $72,000. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PRVA has been the subject of several analyst reports. Canaccord Genuity Group decreased their target price on shares of Privia Health Group from $41.00 to $37.00 and set a “buy” rating for the company in a research note on Tuesday, March 19th. UBS Group lowered their target price on Privia Health Group from $31.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, March 1st. Evercore ISI dropped their target price on Privia Health Group from $26.00 to $25.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 28th. TD Cowen reduced their price target on Privia Health Group from $30.00 to $26.00 and set an “outperform” rating for the company in a report on Friday, March 1st. Finally, JPMorgan Chase & Co. dropped their price objective on Privia Health Group from $38.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, March 6th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.18.

Privia Health Group Stock Down 1.0 %

NASDAQ:PRVA opened at $18.35 on Tuesday. The company has a market cap of $2.18 billion, a PE ratio of 96.58, a P/E/G ratio of 2.53 and a beta of 0.81. The business’s 50 day moving average is $20.29 and its two-hundred day moving average is $21.52. Privia Health Group, Inc. has a 52 week low of $17.54 and a 52 week high of $30.15.

Privia Health Group (NASDAQ:PRVA) last announced its quarterly earnings data on Tuesday, February 27th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. The firm had revenue of $440.80 million for the quarter, compared to the consensus estimate of $425.81 million. During the same quarter last year, the business earned $0.14 earnings per share. The business’s revenue for the quarter was up 21.0% compared to the same quarter last year. As a group, sell-side analysts expect that Privia Health Group, Inc. will post 0.26 EPS for the current fiscal year.

Insider Transactions at Privia Health Group

In related news, CFO David Mountcastle sold 3,933 shares of the business’s stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $17.77, for a total transaction of $69,889.41. Following the completion of the sale, the chief financial officer now owns 262,279 shares of the company’s stock, valued at approximately $4,660,697.83. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director William M. Sullivan sold 9,951 shares of the business’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $23.03, for a total transaction of $229,171.53. Following the completion of the transaction, the director now owns 5,464,533 shares of the company’s stock, valued at $125,848,194.99. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO David Mountcastle sold 3,933 shares of the stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $17.77, for a total transaction of $69,889.41. Following the completion of the sale, the chief financial officer now directly owns 262,279 shares in the company, valued at approximately $4,660,697.83. The disclosure for this sale can be found here. Insiders own 14.20% of the company’s stock.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.